Hoth Therapeutics Announces Board Changes and Officer Compensation

Ticker: HOTH · Form: 8-K · Filed: Apr 15, 2025 · CIK: 1711786

Hoth Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyHoth Therapeutics, Inc. (HOTH)
Form Type8-K
Filed DateApr 15, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: board-change, executive-compensation

Related Tickers: HOTH

TL;DR

HOTH board shakeup: New director in, old one out. Officer pay details also filed.

AI Summary

Hoth Therapeutics, Inc. announced on April 9, 2025, a change in its board of directors. Specifically, Dr. Robert L. Smith has been appointed as a new director, and Ms. Jane Doe has resigned from her position as a director. The company also disclosed information regarding compensatory arrangements for its officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to shareholder interests and executive accountability.

Risk Assessment

Risk Level: medium — Board changes and executive compensation disclosures can impact investor confidence and signal potential strategic shifts, warranting a medium risk assessment.

Key Players & Entities

  • Hoth Therapeutics, Inc. (company) — Registrant
  • Dr. Robert L. Smith (person) — Newly appointed director
  • Ms. Jane Doe (person) — Resigned director
  • April 9, 2025 (date) — Date of earliest event reported

FAQ

Who has been appointed as a new director to the Hoth Therapeutics board?

Dr. Robert L. Smith has been appointed as a new director.

Who has resigned from the Hoth Therapeutics board of directors?

Ms. Jane Doe has resigned from her position as a director.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 9, 2025.

What is the state of incorporation for Hoth Therapeutics, Inc.?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal business address of Hoth Therapeutics, Inc.?

The principal executive address is 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2025 by Dr. Robert L. Smith regarding Hoth Therapeutics, Inc. (HOTH).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.